A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

<p>Abstract</p> <p>Background</p> <p>The anti-EGFR monoclonal antibody cetuximab is used in metastatic colorectal cancer (CRC), and predicting responsive patients garners great interest, due to the high cost of therapy. Mutations in the KRAS gene occur in ~40% of CRC an...

Full description

Bibliographic Details
Main Authors:	Black Esther P, Balko Justin M
Format:	Article
Language:	English
Published:	BMC 2009-05-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/9/145

Similar Items

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
by: Andrea Uhlyarik, et al.
Published: (2020-03-01)

KRAS mutations as a predictor of response to Cetuximab in metastatic colorectal cancer patients
by: Li-Chen Yen, et al.
Published: (2010)

Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma
by: Cheng L, et al.
Published: (2015-11-01)

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer
by: Hung‐Chih Hsu, et al.
Published: (2019-07-01)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
by: Hanna Barmettler, et al.
Published: (2012-08-01)

A polymorphism of <it>EGFR </it>extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment
by: Monges Geneviève, et al.
Published: (2008-06-01)

Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study.
by: Lisanne L Krens, et al.
Published: (2014-01-01)

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
by: Madiha Naseem, et al.
Published: (2021-06-01)

No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
by: Si-wei Zhou, et al.
Published: (2012-01-01)

Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab
by: Justine Bellier, et al.
Published: (2020-02-01)

Beyond <it>KRAS</it> mutation status: influence of <it>KRAS</it> copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
by: Mekenkamp Leonie JM, et al.
Published: (2012-07-01)

In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer.
by: Takahiro Tashiro, et al.
Published: (2017-01-01)

In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer
by: Tashiro, Takahiro
Published: (2018)

Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer.
by: Jan Pander, et al.
Published: (2015-01-01)

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer.
by: L Mineur, et al.
Published: (2020-01-01)

Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study
by: Carmine Pinto, et al.
Published: (2016-11-01)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with <i>RAS</i> Wild Type Metastatic Colorectal Cancer
by: Said A. Khelwatty, et al.
Published: (2021-02-01)

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.
by: Salvatore Siena, et al.
Published: (2013-01-01)

Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.
by: Anita K Gandhi, et al.
Published: (2013-01-01)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
by: Frifeldt Sanne K, et al.
Published: (2011-03-01)

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab
by: Sang-Kyu Lee, et al.
Published: (2018-11-01)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
by: Caglayan Geredeli, et al.
Published: (2018-03-01)

Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.
by: Yu-Lin Lin, et al.
Published: (2014-01-01)

Cetuximab for the first-line treatment of metastatic colorectal cancer
by: C Meads, et al.
Published: (2010-05-01)

Cetuximab in first line treatment of metastatic colorectal cancer
by: Carlo Barone, et al.
Published: (2012-07-01)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
by: S. Gattenlöhner, et al.
Published: (2009-01-01)

Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression
by: Manzari, Mandana T., et al.
Published: (2014)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
by: Dalyong Kim, et al.
Published: (2017-11-01)

Pharmacoeconomic potency assignment of targeted agents in the treatment of metastatic colorectal cancer with wild-type Kras
by: R I Yagudina, et al.
Published: (2013-12-01)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
by: Patel SB, et al.
Published: (2015-12-01)

Cetuximab in treatment of metastatic colorectal cancer: background and clinical observation
by: A. D. Darenskaya, et al.
Published: (2018-11-01)

Efficacy and Immune Mechanisms of Cetuximab for the Treatment of Metastatic Colorectal Cancer
by: Hao Zhuang, et al.
Published: (2011-12-01)

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients
by: Nico B. Volz, et al.
Published: (2020-10-01)

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
by: Chunlong Huang, et al.
Published: (2021-01-01)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
by: Adriana Camargo Carvalho, et al.
Published: (2017-01-01)

Chemotherapy Plus Cetuximab versus Chemotherapy Alone for Patients with KRAS Wild Type Unresectable Liver-Confined Metastases Colorectal Cancer: An Updated Meta-Analysis of RCTs
by: W. Lv, et al.
Published: (2017-01-01)

Mutational analysis of KRAS and NRAS in metastatic colorectal cancer
by: Romina Oliveira Silva
Published: (2019)

A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial
by: Shigeyoshi Iwamoto, et al.
Published: (2018-09-01)

Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with <i>KRAS</i> p.G13D Mutation
by: Tomokazu Ohishi, et al.
Published: (2020-08-01)

THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND ENHANCING RESPONSE TO TARGETED EGFR THERAPY
by: Balko, Justin M.
Published: (2009)

Cannot write session to /tmp/vufind_sessions/sess_k1v91b6u3ollv3i0oej4ltledj